pilot-plant-of-chime-biologics-2
not available.
News
Chime Biologics Partners Polpharma Biologics to Advance Global Biosimilar Development
Chime Biologics Partners Polpharma Biologics to Advance Global Biosimilar Development Accelerate Polpharma Biologics biosimilar program from IND to commercial manufacturing Includes a commitment to producing for US FDA BLA submission Expand global market presence through launch in EU and other regions April 16, 2025, Gdańsk, Poland and Shanghai, China – Chime Biologics, a leading global […]
Chime Biologics and Great Bay Bio deepen strategic cooperation, using AI to accelerate the development of biopharmaceuticals
Chime Biologics and Great Bay Bio deepen strategic cooperation, using AI to accelerate the development of biopharmaceuticals Not availible.
Chime Biologics Supports Mabgeek to Advance MG-K10 into Phase III Trials and Enter the U.S. Market
Chime Biologics Supports Mabgeek to Advance MG-K10 into Phase III Trials and Enter the U.S. Market February 21, 2025, Shanghai – Chime Biologics, a leading global CDMO that enables its partners’ success in biologics, today announced its continued collaboration with Mabgeek in advancing MG-K10, a potential Best-in-Class therapy, a novel IL-4Rα-targeting antibody drug for atopic […]
chime biologics and mabgeek celebrate ppq success
chime biologics and mabgeek celebrate ppq success Not available.
Chime Biologics and Mabgeek Achieve MG-K10 PPQ Milestone, Advancing Atopic Dermatitis and Asthma Therapies Antibody Drug MG-K10 Late-Stage Clinical Trials and Commercialization
Chime Biologics and Mabgeek Achieve MG-K10 PPQ Milestone, Advancing Atopic Dermatitis and Asthma Therapies Antibody Drug MG-K10 Late-Stage Clinical Trials and Commercialization -Process Performance Qualification (PPQ) validates robust manufacturing standards and is crucial for regulatory compliance -Marks a key step forward for the world’s first once-monthly IL-4Rα-targeting antibody therapeutic for Th2-driven diseases, with a strategic […]
Chime Biologics and Waterstone Announce a Strategic Partnership to Empower Antibody-Drug Conjugate (ADC) Development and Manufacturing
Chime Biologics and Waterstone Announce a Strategic Partnership to Empower Antibody-Drug Conjugate (ADC) Development and Manufacturing Chime Biologics and Waterstone Pharmaceuticals announce a strategic partnership to provide integrated services for the global Antibody-Drug Conjugate (ADC) industry. Chime Biologics will leverage its CMC expertise in biologics to manage Antibody Intermediate, ADC Drug Substance and Drug Product, […]
Chime Biologics Bridges Innovation and Collaboration at Europe-China Biotech Business Forum 2024
Chime Biologics Bridges Innovation and Collaboration at Europe-China Biotech Business Forum 2024 November 4, Stockholm, Sweden – Chime Biologics, a leading global CDMO that enables its partners’ success in biologics, bridged Europe-Asia Biotech innovation and collaboration at the Europe-China Biotech Business Forum 2024, a BIO-Europe side event. Bringing together senior pharmaceutical leaders to explore cross-border […]